腎臓がん治療薬市場：タイプ別、薬剤クラス別、治療クラス別-2025-2030年の世界予測

腎臓がん治療薬市場は、2023年に58億米ドルと評価され、2024年には61億4,000万米ドルに達すると予測され、CAGR 5.97％で成長し、2030年には87億1,000万米ドルに達すると予測されています。

腎臓がん治療薬市場は、主に生物学的製剤、低分子阻害剤、免疫療法に焦点を当てた、腎がんに対する医薬品治療の範囲と用途によって定義されます。これらの薬剤の必要性は、高齢者人口の増加や喫煙、肥満などの生活習慣に関連するリスクなどの要因によって、世界的に腎臓がんの発生率が上昇していることによって強調されています。治療は標的療法、免疫療法、化学療法に及び、第一選択薬や補助療法として使用されることが多いです。最終用途の範囲には主に病院、がん研究機関、専門クリニックが含まれ、患者の生存率と生活の質を改善するためにこれらの薬剤に依存しています。

市場成長は、早期発見のためのバイオマーカーの進歩、併用療法の開発、個別化医療に焦点を当てた大規模な研究投資によって大きく左右されます。最新のビジネスチャンスは、ヘルスケアへのアクセスが向上し、がんに対する意識が高まっている、拡大する地域市場に見出されます。研究開発のための戦略的提携や、創薬のための人工知能の活用は、市場の存在感をさらに高める可能性があります。しかし、同市場は高い治療費、厳しい規制の枠組み、患者のコンプライアンスを妨げる腎臓がん治療薬の潜在的な副作用などの制約に直面しています。さらに、バイオシミラーとの競合が市場の既存企業に課題を突きつけています。

遺伝子治療、ドラッグデリバリー用の生分解性ナノ粒子、天然化合物誘導体の探索といった分野では、技術革新が進む可能性があります。治療法を個別化するために遺伝子プロファイリングに基づく精密医療を重視することは、事業成長の鍵となる分野です。全体として、市場は競争が激しくダイナミックであり、進行中の研究や臨床試験が将来の軌道を形成しています。市場機会を活用しようとする企業は、戦略的提携、継続的イノベーション、研究パイプラインの拡充に注力し、競争力を維持すべきです。また、患者教育・支援プログラムの充実も、市場の課題を克服する上で重要な役割を果たします。

市場力学：急速に進化する腎臓がん治療薬市場における主要市場インサイトの解明

腎臓がん治療薬市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。こうした動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響についてより明確に理解することができます。

• 市場促進要因
  • がん患者の急増
  • 高血圧や糖尿病を患う老年人口の増加
  • 喫煙、飲酒、加工食品の摂取を含むライフスタイルの変化の増加
• 市場抑制要因
  • 治療に伴う合併症のリスク
• 市場機会
  • 新薬の入手可能性と強力なパイプラインの存在
  • 研究開発投資の増加とメーカー間の協力関係
• 市場の課題
  • 厳しい規制政策

ポーターの5つの力：腎臓がん治療薬市場をナビゲートする戦略ツール

ポーターのファイブフォース（5つの力）は、腎臓がん治療薬市場の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することで、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：腎臓がん治療薬市場における外部からの影響の把握

外部マクロ環境要因は、腎臓がん治療薬市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析腎臓がん治療薬市場における競合情勢の把握

腎臓がん治療薬市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス腎臓がん治療薬市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、腎臓がん治療薬市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨腎臓がん治療薬市場における成功への道筋を描く

腎臓がん治療薬市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • がん患者の増加
    • 高血圧や糖尿病を患う高齢者人口の増加
    • 喫煙、飲酒、加工食品の摂取などライフスタイルの変化の増加
  • 抑制要因
    • 治療に伴う合併症のリスク
  • 機会
    • 新薬の入手可能性と強力なパイプラインの存在
    • メーカー間の連携と相まって研究開発投資が増加
  • 課題
    • 厳格な規制政策
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 腎臓がん治療薬市場：タイプ別

• クロモフォビア
• クリアセル
• 集合管
• 腫瘍細胞
• 乳頭状

第7章 腎臓がん治療薬市場薬理学的クラス別

• 血管新生阻害剤
• サイトカイン免疫療法
• モノクローナル抗体
• MTOR阻害剤

第8章 腎臓がん治療薬市場治療クラス別

• 免疫療法
• 標的療法

第9章 南北アメリカの腎臓がん治療薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域の腎臓がん治療薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの腎臓がん治療薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Amgen, Inc.
• AVEO Pharmaceuticals, Inc.
• Bayer AG
• Bristol-Myers Squibb Company
• Eisai Co., Ltd.
• Exelixis, Inc.
• Genentech, Inc.
• GlaxoSmithKline PLC
• NanoString Technologies, Inc.
• NeoGenomics Laboratories, Inc.
• Novartis AG
• Pfizer Inc.
• Prometheus Laboratories Inc.
• Sun Pharmaceutical Industries Limited
• Thermo Fisher Scientific Inc.

LIST OF FIGURES

• FIGURE 1. KIDNEY CANCER DRUGS MARKET RESEARCH PROCESS
• FIGURE 2. KIDNEY CANCER DRUGS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS KIDNEY CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS KIDNEY CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES KIDNEY CANCER DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES KIDNEY CANCER DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC KIDNEY CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC KIDNEY CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA KIDNEY CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA KIDNEY CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. KIDNEY CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. KIDNEY CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. KIDNEY CANCER DRUGS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. KIDNEY CANCER DRUGS MARKET DYNAMICS
• TABLE 7. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY CHROMOPHOBE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY CLEAR CELL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY COLLECTING DUCT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY ONCOCYTIC, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY PAPILLARY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY ANGIOGENESIS INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY CYTOKINE IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY MTOR INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 22. AMERICAS KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 23. AMERICAS KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 24. AMERICAS KIDNEY CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 25. ARGENTINA KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 26. ARGENTINA KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 27. ARGENTINA KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 28. BRAZIL KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 29. BRAZIL KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 30. BRAZIL KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 31. CANADA KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 32. CANADA KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 33. CANADA KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 34. MEXICO KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 35. MEXICO KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 36. MEXICO KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 37. UNITED STATES KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 38. UNITED STATES KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 39. UNITED STATES KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 40. UNITED STATES KIDNEY CANCER DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 41. ASIA-PACIFIC KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 42. ASIA-PACIFIC KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 43. ASIA-PACIFIC KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 44. ASIA-PACIFIC KIDNEY CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 45. AUSTRALIA KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 46. AUSTRALIA KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 47. AUSTRALIA KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 48. CHINA KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 49. CHINA KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 50. CHINA KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 51. INDIA KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 52. INDIA KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 53. INDIA KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 54. INDONESIA KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 55. INDONESIA KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 56. INDONESIA KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 57. JAPAN KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 58. JAPAN KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 59. JAPAN KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 60. MALAYSIA KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 61. MALAYSIA KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 62. MALAYSIA KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 63. PHILIPPINES KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 64. PHILIPPINES KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 65. PHILIPPINES KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 66. SINGAPORE KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 67. SINGAPORE KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 68. SINGAPORE KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 69. SOUTH KOREA KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 70. SOUTH KOREA KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 71. SOUTH KOREA KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 72. TAIWAN KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 73. TAIWAN KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 74. TAIWAN KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 75. THAILAND KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 76. THAILAND KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 77. THAILAND KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 78. VIETNAM KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 79. VIETNAM KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 80. VIETNAM KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 81. EUROPE, MIDDLE EAST & AFRICA KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 82. EUROPE, MIDDLE EAST & AFRICA KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 83. EUROPE, MIDDLE EAST & AFRICA KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 84. EUROPE, MIDDLE EAST & AFRICA KIDNEY CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 85. DENMARK KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 86. DENMARK KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 87. DENMARK KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 88. EGYPT KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 89. EGYPT KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 90. EGYPT KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 91. FINLAND KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 92. FINLAND KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 93. FINLAND KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 94. FRANCE KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 95. FRANCE KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 96. FRANCE KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 97. GERMANY KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 98. GERMANY KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 99. GERMANY KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 100. ISRAEL KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 101. ISRAEL KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 102. ISRAEL KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 103. ITALY KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 104. ITALY KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 105. ITALY KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 106. NETHERLANDS KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 107. NETHERLANDS KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 108. NETHERLANDS KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 109. NIGERIA KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 110. NIGERIA KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 111. NIGERIA KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 112. NORWAY KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 113. NORWAY KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 114. NORWAY KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 115. POLAND KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 116. POLAND KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 117. POLAND KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 118. QATAR KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 119. QATAR KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 120. QATAR KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 121. RUSSIA KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 122. RUSSIA KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 123. RUSSIA KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 124. SAUDI ARABIA KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 125. SAUDI ARABIA KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 126. SAUDI ARABIA KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 127. SOUTH AFRICA KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 128. SOUTH AFRICA KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 129. SOUTH AFRICA KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 130. SPAIN KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 131. SPAIN KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 132. SPAIN KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 133. SWEDEN KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 134. SWEDEN KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 135. SWEDEN KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 136. SWITZERLAND KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 137. SWITZERLAND KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 138. SWITZERLAND KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 139. TURKEY KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 140. TURKEY KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 141. TURKEY KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 142. UNITED ARAB EMIRATES KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 143. UNITED ARAB EMIRATES KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 144. UNITED ARAB EMIRATES KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 145. UNITED KINGDOM KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 146. UNITED KINGDOM KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 147. UNITED KINGDOM KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 148. KIDNEY CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 149. KIDNEY CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

The Kidney Cancer Drugs Market was valued at USD 5.80 billion in 2023, expected to reach USD 6.14 billion in 2024, and is projected to grow at a CAGR of 5.97%, to USD 8.71 billion by 2030.

The kidney cancer drugs market is defined by the scope and application of pharmaceutical treatments for renal cancers, primarily focusing on biologics, small-molecule inhibitors, and immunotherapies. The necessity for these drugs is underscored by the rising incidence of kidney cancer globally, driven by factors such as increasing geriatric population and lifestyle-related risks like smoking and obesity. Applications span targeted therapy, immunotherapy, and chemotherapy, often employed as first-line or adjuvant treatments. The end-use scope predominantly includes hospitals, cancer research institutes, and specialty clinics, which rely on these drugs to improve survival rates and quality of life for patients.

Market growth is significantly influenced by advancements in biomarkers for early detection, the development of combination therapies, and substantial research investments focusing on personalized medicine. The latest opportunities are found in expanding geographic markets where increasing healthcare access and rising cancer awareness are prevalent. Strategic collaborations for R&D and leveraging artificial intelligence for drug discovery can further enhance market presence. However, the market faces limitations such as high treatment costs, stringent regulatory frameworks, and potential side effects of kidney cancer drugs, which can hinder patient compliance. Additionally, competition from biosimilars poses a challenge to market incumbents.

Innovation can thrive in the areas of gene therapy, biodegradable nanoparticles for drug delivery, and the exploration of natural compound derivatives. Emphasizing precision medicine based on genetic profiling to personalize treatment options presents a key area for business growth. Overall, the market is highly competitive and dynamic, with ongoing research and clinical trials shaping its future trajectory. Companies aiming to capitalize on market opportunities should focus on strategic alliances, continuous innovation, and expanding their research pipeline to maintain a competitive edge. Enhanced patient education and support programs can also play a crucial role in overcoming market challenges.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Kidney Cancer Drugs Market

The Kidney Cancer Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Proliferation in the number of people suffering from cancer
  • Growing geriatric population with hypertension and diabetes
  • Increasing lifestyle changes including smoking, drinking, and consumption of processed food
• Market Restraints
  • Risk of complications associated with treatment
• Market Opportunities
  • Availability of novel drugs and the presence of a strong pipeline
  • Increasing research and development investment coupled with collaborations among manufacturers
• Market Challenges
  • Stringent regulatory policies

Porter's Five Forces: A Strategic Tool for Navigating the Kidney Cancer Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Kidney Cancer Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Kidney Cancer Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Kidney Cancer Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Kidney Cancer Drugs Market

A detailed market share analysis in the Kidney Cancer Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Kidney Cancer Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Kidney Cancer Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Kidney Cancer Drugs Market

A strategic analysis of the Kidney Cancer Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Kidney Cancer Drugs Market, highlighting leading vendors and their innovative profiles. These include Amgen, Inc., AVEO Pharmaceuticals, Inc., Bayer AG, Bristol-Myers Squibb Company, Eisai Co., Ltd., Exelixis, Inc., Genentech, Inc., GlaxoSmithKline PLC, NanoString Technologies, Inc., NeoGenomics Laboratories, Inc., Novartis AG, Pfizer Inc., Prometheus Laboratories Inc., Sun Pharmaceutical Industries Limited, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Kidney Cancer Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Chromophobe, Clear Cell, Collecting Duct, Oncocytic, and Papillary.
• Based on Pharmacologic Class, market is studied across Angiogenesis Inhibitors, Cytokine Immunotherapy, Monoclonal Antibodies, and MTOR Inhibitors.
• Based on Therapeutic Class, market is studied across Immunotherapy and Targeted Therapy.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Proliferation in the number of people suffering from cancer
    • 5.1.1.2. Growing geriatric population with hypertension and diabetes
    • 5.1.1.3. Increasing lifestyle changes including smoking, drinking, and consumption of processed food
  • 5.1.2. Restraints
    • 5.1.2.1. Risk of complications associated with treatment
  • 5.1.3. Opportunities
    • 5.1.3.1. Availability of novel drugs and the presence of a strong pipeline
    • 5.1.3.2. Increasing research and development investment coupled with collaborations among manufacturers
  • 5.1.4. Challenges
    • 5.1.4.1. Stringent regulatory policies
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Kidney Cancer Drugs Market, by Type

• 6.1. Introduction
• 6.2. Chromophobe
• 6.3. Clear Cell
• 6.4. Collecting Duct
• 6.5. Oncocytic
• 6.6. Papillary

7. Kidney Cancer Drugs Market, by Pharmacologic Class

• 7.1. Introduction
• 7.2. Angiogenesis Inhibitors
• 7.3. Cytokine Immunotherapy
• 7.4. Monoclonal Antibodies
• 7.5. MTOR Inhibitors

8. Kidney Cancer Drugs Market, by Therapeutic Class

• 8.1. Introduction
• 8.2. Immunotherapy
• 8.3. Targeted Therapy

9. Americas Kidney Cancer Drugs Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Kidney Cancer Drugs Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Kidney Cancer Drugs Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Amgen, Inc.
• 2. AVEO Pharmaceuticals, Inc.
• 3. Bayer AG
• 4. Bristol-Myers Squibb Company
• 5. Eisai Co., Ltd.
• 6. Exelixis, Inc.
• 7. Genentech, Inc.
• 8. GlaxoSmithKline PLC
• 9. NanoString Technologies, Inc.
• 10. NeoGenomics Laboratories, Inc.
• 11. Novartis AG
• 12. Pfizer Inc.
• 13. Prometheus Laboratories Inc.
• 14. Sun Pharmaceutical Industries Limited
• 15. Thermo Fisher Scientific Inc.